Aries Wealth Management Takes $211,000 Position in Zimmer Biomet Holdings Inc (ZBH)

Aries Wealth Management bought a new stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) during the fourth quarter, Holdings Channel reports. The institutional investor bought 1,710 shares of the medical equipment provider’s stock, valued at approximately $211,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZBH. QS Investors LLC grew its stake in Zimmer Biomet by 9.4% in the second quarter. QS Investors LLC now owns 9,326 shares of the medical equipment provider’s stock valued at $1,197,000 after purchasing an additional 800 shares in the last quarter. Janus Henderson Group PLC grew its stake in Zimmer Biomet by 100.0% in the second quarter. Janus Henderson Group PLC now owns 135,304 shares of the medical equipment provider’s stock valued at $17,372,000 after purchasing an additional 67,657 shares in the last quarter. Cornerstone Capital Management Holdings LLC. grew its stake in Zimmer Biomet by 9.8% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 38,098 shares of the medical equipment provider’s stock valued at $4,891,000 after purchasing an additional 3,412 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in Zimmer Biomet by 3.9% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 22,159 shares of the medical equipment provider’s stock valued at $2,845,000 after purchasing an additional 823 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC purchased a new position in Zimmer Biomet in the second quarter valued at about $202,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Zimmer Biomet Holdings Inc (NYSE ZBH) opened at $120.78 on Thursday. Zimmer Biomet Holdings Inc has a 12-month low of $108.03 and a 12-month high of $133.49. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52. The firm has a market capitalization of $24,940.64, a PE ratio of 13.41, a P/E/G ratio of 2.16 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the consensus estimate of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The business had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same quarter in the previous year, the firm earned $2.14 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio is presently 10.65%.

Several research firms have recently issued reports on ZBH. Cantor Fitzgerald reiterated a “buy” rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Tuesday, January 30th. BMO Capital Markets reiterated a “buy” rating and set a $144.00 price target on shares of Zimmer Biomet in a research note on Tuesday, January 30th. Morgan Stanley upped their price target on Zimmer Biomet from $140.00 to $150.00 in a research note on Monday, January 29th. SunTrust Banks upped their price target on Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a research note on Monday, January 29th. Finally, Needham & Company LLC upped their price target on Zimmer Biomet from $144.00 to $155.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $141.67.

ILLEGAL ACTIVITY WARNING: “Aries Wealth Management Takes $211,000 Position in Zimmer Biomet Holdings Inc (ZBH)” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://sportsperspectives.com/2018/02/08/aries-wealth-management-takes-211000-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply